Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo Pharma
December 18, 2023 06:30 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of America's Most Successful Small-Cap Companies
December 05, 2023 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced its inclusion in Forbes' esteemed list of America's Most...
Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update
November 08, 2023 16:11 ET
|
Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results
Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®
November 02, 2023 10:37 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Scinai Reports Third Quarter 2023 Financial Results and Provides Business Update
October 31, 2023 08:23 ET
|
Scinai Immunotherapeutics Ltd.
JERUSALEM, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via IBN -- Scinai Immunotherapeutics Ltd (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative...
Catalyst Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 8, 2023
October 23, 2023 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...
Catalyst Pharmaceuticals Announces FDA Acceptance of the Supplemental New Drug Application for FIRDAPSE®
October 13, 2023 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
The sNDA Seeks to Increase the Indicated Maximum Daily Dose for FIRDAPSE to 100mg for the Treatment of Lambert-Eaton Myasthenic Syndrome U.S. FDA Assigned Target Action Date of June 4, 2024 CORAL...
Multiplex Detection Immunoassays Market Revenue to Cross USD 3.6 billion by 2030, Rising at a 7.5% CAGR: TMR Report
September 20, 2023 09:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The multiplex detection immunoassays market was estimated to have acquired US$ 1.5 billion...
GRI Bio Enters into Asset Purchase Agreement with Aardvark Therapeutics, Inc. for the Sale of Legacy Asset, ADAIR
August 23, 2023 09:00 ET
|
GRI Bio, Inc.
Aardvark to acquire global development and commercialization rights to ADAIR and all intellectual property outside of Europe and licensor rights for the EU Aardvark to leverage ADAIR formulation...
Catalyst Pharmaceuticals Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer
August 16, 2023 10:56 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...